Gilead Sciences has successfully cleared the final regulatory approvals for its acquisition of Arcellx, a biotechnology company specializing in cell therapy technologies. Following this development, holders of Arcellx shares now have an additional three days to decide whether to sell their holdings or wait for the deal's completion. The transaction is part of Gilead's strategic effort to expand its capabilities in immunology and oncology through advanced cell manufacturing and delivery platforms. While the specific financial terms of the merger, including the deal value per share, were not detailed in the provided text due to a technical error on the news source, the timeline indicates that regulatory hurdles have now been overcome. StockTitan notes this update under the headline "Arcellx holders get 3 more days as Gilead clears final deal approvals." The acquisition represents a significant consolidation of resources between two entities with overlapping interests in developing cell-based medicines, potentially accelerating Gilead's pipeline development in areas such as CAR-T therapies and other cellular immunotherapies. The technical difficulties encountered by the news source, which displayed a connection timeout error from www.stocktitan.net, prevented full details from loading beyond this summary. The available information confirms that Arcellx shareholders are being given a short extension to consider their options as the deal moves closer to closing. Gilead's successful regulatory clearance marks an important milestone in the integration process, although specific dates for the expected completion were not included in the accessible content.